The PE Ratio as of November 2024 (TTM) for SAB Biotherapeutics, Inc. (SABS) is -0.50

According to SAB Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.50. This represents a change of -49.76% compared to the average of -1.00 of the last 4 quarters.

SAB Biotherapeutics, Inc. (SABS) Historical PE Ratio (quarterly & annually)

How has SABS PE Ratio performed in the past?

The mean historical PE Ratio of SAB Biotherapeutics, Inc. over the last ten years is -94.05. The current -0.50 PE Ratio has changed -46.84% with respect to the historical average. Over the past ten years (40 quarters), SABS's PE Ratio was at its highest in in the March 2021 quarter at 75.70. The PE Ratio was at its lowest in in the December 2020 quarter at -4172.43.

SAB Biotherapeutics, Inc. (SABS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of SAB Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

SAB Biotherapeutics, Inc. (SABS) Average PE Ratio

How has SABS PE Ratio performed in the past?

The current PE Ratio of SAB Biotherapeutics, Inc. (SABS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

SAB Biotherapeutics, Inc. (SABS) PE Ratio vs. Peers

How is SABS’s PE Ratio compared to its peers?

SAB Biotherapeutics, Inc.’s PE Ratio is less than Comera Life Sciences Holdings, Inc. (0), less than Processa Pharmaceuticals, Inc. (-0.00), less than Fresh Tracks Therapeutics, Inc. (-0.24), greater than Third Harmonic Bio, Inc. (-3.00), greater than Cingulate Inc. (-44.42), less than Anebulo Pharmaceuticals, Inc. (-0.00), greater than Cadrenal Therapeutics, Inc. Common Stock (-4.78), greater than Monopar Therapeutics Inc. (-2.18), greater than Unicycive Therapeutics, Inc. (-0.54), greater than Quoin Pharmaceuticals, Ltd. (-1.63), less than Cardio Diagnostics Holdings, Inc. (-0.33), greater than Virax Biolabs Group Limited (-0.79), greater than PaxMedica, Inc. Common Stock (-0.67), less than null (-0.04),

Build a custom stock screener for SAB Biotherapeutics, Inc. (SABS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SAB Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SAB Biotherapeutics, Inc. (SABS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SAB Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.